Business Wire

Group Financial Results as of June 30th 2023, Approved Solid Financial Performance, With Continued EBITDA Margin Expansion


The Board of Directors of Nexi S.p.A. approved on July 31st the Group’s consolidated financial results as of June 30th 2023.

“This first half of the year confirms a solid and profitable growth in all our businesses and in the different geographic areas in which we operate, despite the ongoing uncertain macroeconomic situation," commented Paolo Bertoluzzo, CEO of Nexi Group. "We are progressing with our development with great rationality and discipline, investing in the areas with the greatest growth potential, increasingly focusing our business portfolio and accelerating cash generation, to the benefit of our shareholders. In an increasingly competitive digital payments market, our goal remains to strengthen our European leadership position in the industry, supporting the digital development of the countries in which we operate."

In 2Q23 the acquiring volumes1 registered a sustained volume growth in all geographies, despite tough Y/Y comparison due to Covid-19 re-openings in 2Q22. Compared to 2019, there has been an acceleration of volumes in 1H23, reaching approximately 30%+ across all geographies in June. The volume growth rates across different categories started to converge towards more normalised levels, post Covid-19.

Key consolidated financial managerial results 2

In 1H23 the Group delivered solid financial results, with revenues reaching € 1,577.0 million, +8.1% versus 1H22, and EBITDA reaching € 771.8 million, +11.6% versus 1H22. The EBITDA Margin was at 49%, up by 153 basis points compared to 1H22.
In 2Q23, revenues reached € 835.3 million, +7.3% versus 2Q22 and EBITDA was at € 436.1 million, +10.1% versus 2Q22, with EBITDA Margin at 52%.

Nexi Group’s operating businesses delivered the following results in 1H23:

Merchant Solutions, representing approximately 56% of Group's total revenues, reported revenues of € 886.4 million, +9.8% Y/Y. In 1H23 8,766 million transactions were processed, +14.9% Y/Y, with value of processed transactions at € 392.0 billion, +9.7% Y/Y. Transactions value growth continued across the Group, primarily driven by international schemes, coupled with continued strong growth of customer base and number of terminals.

In 2Q23, Merchant Solutions revenues reached € 473.9 million, +8.3% Y/Y, despite tough Y/Y comparison.

The main initiatives realized in Merchant Solutions during 1H23 include:

  • ISVs partnership: with new partnership wins in both ECRs and vertical specialists in hospitality and retail;
    • Progress on roll-out of SME capabilities and best practices across markets. SoftPOS roll-out across geographies progressing;
    • Strategic partnership with Computop, the leading eCommerce provider in Germany, strengthening our online and omnichannel proposition across all verticals in DACH and beyond;
    • Continued strengthening of the partnerships (e.g., with eCom enabler Shopware). Additionally, a preferred partnership with Shopify has been signed in Poland;
    • Continued progress of LAKA propositions evolution, including data-enabled insights suite in Nordics and progress in unattended capabilities for hospitality & EV charging.
  • Issuing Solutions, representing approximately 33% of Group's total revenues, reported revenues of € 516.5 million, +8.2% Y/Y. In 1H23 9,178 million transactions were processed, +12.2% Y/Y, with value of processed transactions at € 425.4 billion, +9.3% Y/Y. Transaction volumes showed a sustained growth versus last year, mainly driven by international schemes.
    In 2Q23, Issuing Solutions reached € 270.0 million of revenues, +8.2% Y/Y. In particular, the quarterly performance in Italy has been sustained by positive volume mix, acceleration of international debit, and one-off contribution related to banks’ M&A.
  • Digital Banking Solutions, representing approximately 11% of Group's total revenues, reported revenues of € 174.2 million, +0.3% Y/Y, with strong volume growth broadly offset by impacts from banking consolidation in Italy in 2022.
    In 2Q23, Digital Banking Solutions reached € 91.4 million of revenues, stable Y/Y.

In 1H23, Total Costs were at € 805.2 million, up by 5.0% Y/Y, due to volume and business growth, people investments in key strategic areas and inflationary pressure. In 2Q23 Total Costs were at € 399.2 million, +4.4% versus 2Q22, normalised after the peak in 1Q23.

Nexi confirmed its commitment on investments in technology and innovation, with total Capex3 at € 230 million for 1H23, equal to 15% net revenues. In particular, € 78 million were related to transformation and integration initiatives, and € 152 million were related to the ordinary innovation of products and services, maintenance of high-quality services and security, POS and ATM purchase and strategic one-off infrastructure renewals.

Continued strong reduction of transformation and integration costs at € 54.0 million, down 25% versus 1H22; non-recurring items below EBITDA decreased to € 79.1 million in 1H23.

During the semester the Group delivered strong EBITDA minus Capex and non-recurring cash items performance at +18.4% Y/Y.

Normalised net profit4 in 1H23 was € 295.0 million, with normalised EPS at 0.22 € up by 8.0% Y/Y.

The excess cash generation was equal to € 270,5 million in 1H23.

As of June 30th 2023, the Net Financial Debt was at € 5,422 million, while the Net Financial Debt/ EBITDA ratio reached 3.2x. The pro-forma Net Financial Debt / EBITDA ratio including the run-rate synergies was at ~2.8x, in line with the plan. The weighted average maturity is ~3.6 years with an average pre-tax cash cost of debt at ~2.8%. 2024 maturities are expected to be met with existing cash resources triggering a gross debt reduction.

Group strategy execution progressing well, with expected ~2.8€B organic excess cash generated in 2023-25. At least € 1.5 billion earmarked for debt reduction, still leaving plenty of room for returning cash to shareholders and strategic value accretive M&A.

2023 Guidance

Nexi confirms the 2023 Guidance in line with CMD medium-long term growth ambition:

  • Net revenues: more than 7% Y/Y growth;
  • EBITDA: more than 10% Y/Y growth;
  • Excess cash generation: at least € 600 million5;
  • Net leverage: ~3.0x EBITDA (~2.7x EBITDA incl. run-rate synergies) including the acquisition of Sabadell merchant book (announced in February 2023, closing expected in 4Q23);
  • Normalised EPS: more than 10% Y/Y growth.

Significant subsequent events

In addition, Nexi informs that Mr. Jeffrey David Paduch, a non-executive and non-independent Director, has submitted effective as of 31 July 2023 his resignation due to new professional commitments. The Board of Directors unanimously thanks Mr. Jeffrey David Paduch for his professional contribution. Based on the communications to the Company and to the public, at the time of the resignation Mr. Jeffrey David Paduch does not hold any shares of the Company.

In light of the above, the Board of Directors of the Company during yesterday’s meeting, appointed by co-optation Mr. Francesco Casiraghi as a non-executive and non-independent Director, after the favorable opinion of the Board of Statutory Auditors. His curriculum vitae is available on the website at the following link

Mr. Francesco Casiraghi will remain in post until the next Shareholders' Meeting and, as of today, does not own any shares in Nexi.

* * *

Pursuant to paragraph 2 of article 154 bis of the Consolidated Finance Act, the undersigned, Enrico Marchini, in his capacity as the manager in charge of preparing Nexi’s financial reports, declares that the accounting information contained in this press release corresponds to the accounting documents, books and records of Nexi S.p.A..

Reported results under review by PricewaterhouseCoopers that will release limited revision.

* * *

Disclaimer: This is the English translation of the original Italian press release “Approvati i risultati finanziari di Gruppo al 30 giugno 2023”. In any case of discrepancy between the English and the Italian versions, the original Italian document is to be given priority of interpretation for legal purposes.


Nexi is Europe's PayTech company operating in high-growth, attractive European markets and technologically advanced countries. Listed on Euronext Milan, Nexi has the scale, geographic reach and abilities to drive the transition to a cashless Europe. With its portfolio of innovative products, e-commerce expertise and industry-specific solutions, Nexi provides flexible support for the digital economy and the entire payment ecosystem globally, across a broad range of different payment channels and methods. Nexi’s technological platform and the best-in-class professional skills in the sector enable the company to operate at its best in three market segments: Merchant Solutions, Issuing Solutions and Digital Banking Solutions. Nexi constantly invests in technology and innovation, focusing on two fundamental principles: meeting, together with its partner banks, customer needs and creating new business opportunities for them. Nexi is committed to supporting people and businesses of all sizes, transforming the way people pay and businesses accept payments. It offers companies the most innovative and reliable solutions to better serve their customers and expand. By simplifying payments and enabling people and businesses to build closer relationships and grow together, Nexi promotes progress to benefit everyone.

1H 2023 P&L – Reported vs Normalised

Reported data at current FX with ISP merchant book acquisition in Croatia consolidated from February 28th 2023. Normalised data pro-forma for M&A (i.e. ISP merchant book acquisition in Croatia consolidated from January 1st 2023), at constant FX and excluding non‐recurring items and other one-offs (e.g. D&A of customer contracts).

Income Statement

Balance Sheet

1 Volumes data include sales, International schemes and exclude SIA. For Italy: data also include national schemes for ISP merchant book only. For Nordics and DACH region: data include regular business and exclude non-card based transactions from e-commerce.
2 2022 and 2023 pro-forma normalised managerial data at constant FX and scope (for the M&A recently closed - i.e. ISP merchant book acquisition in Croatia).
3 Managerial figure.
4 Net profit to which non-recurring items and D&A customer contracts are added back net of taxes.
5 Gross of c.100€M deferred taxes in 2023.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Nexi - External Communication & Media Relations
Daniele de Sanctis
Mobile: +39 346/015.1000

Matteo Abbondanza
Mobile: +39.348/406.8858

Søren Winge
Mobile: +45 29 48 26 35

Danja Giacomin
Mobile: +39.334/225.6777

Nexi - Investor Relations
Stefania Mantegazza
Mobile: +39.335.5805703
Direct: +39 02/3488.8216

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PUMA Called Ambassadors From All Around the World to Form “Class of 23”1.10.2023 13:00:00 EEST | Press release

Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. This press release features multimedia. View the full release here: Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. (Photo: Business Wire) 2023 means a long journey for PUMA, which was made with the remarkable people behind it. ​“Class of 23” is the right way to celebrate the inspiring ambassadors and talents PUMA has collaborated with over the past 75 years. Each talent, from Neymar Jr. and Pamela Reif to Gianmarco Tamberi and Winnie Harlow, was captured in a personalized way, wearing their favorite PUMA beanies from the 2023 collection to show their membership in the grand PUMA family. “Our PUMA family is the heartbeat of our brand, co-created with the brilliance

Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 20231.10.2023 09:00:00 EEST | Press release

Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear). Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP. This press release features multimedia. View the full release here: Advancing data transmission rates to 100Gbps per lane drastically transforms the ecosystem of data centers, especially AI/ML and HPC. Training AI and GPT workloads drive huge and high-density networks utilizing large numbers of servers connected together through rack switches over short reach links. The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications. Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an

Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release

GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom